Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medicago has announced plans to invest around $4m to increase the capacity of the pilot production facility located in Quebec City, the capital of the Canadian province of Quebec.
Subscribe to our email newsletter
The new investment includes capital expenditures and labour costs, as well as preclinical studies for a rabies vaccine and other products.
The company anticipates this investment to enhance preclinical and clinical development timelines of future product candidates.
In 2009, Medicago was awarded $1.77m in funding by the Quebec Consortium for Drug Discovery (CQDM) to support the development of VLPExpress, an automated platform to identify the best antigen presentations for a disease-causing agent.
Medicago is a clinical-stage biopharmaceutical company focused on focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs).